Ki16198 NEW

Price	$48	$83	$173
Package	5mg	10mg	25mg

Min. Order:
Supply Ability:	10g
Update Time:	2024-11-19

Product Details

Product Name: Ki16198	CAS No.: 355025-13-7
Purity: 97.6%	Supply Ability: 10g
Release date: 2024/11/19

Product Introduction

Bioactivity

Name	Ki16198
Description	Ki16198 is an orally available LPA receptor antagonist and is a methyl ester derivative of Ki16425. It inhibits LPA1- and LPA3-induced inositol phosphates with Ki values of 0.34 and 0.93 μM, respectively, and can be used in studies of pancreatic carcinogenesis and metastasis.
In vitro	Saxagliptin has an inhibition constant Ki of 1.3 nM for DPP4 inhibition, which is 10-fold more potent than either vildagliptin or sitagliptin (another two DPP4 inhibitors) with Ki of 13 and 18 nM. In addition, Saxagliptin demonstrates greater specificity for DPP4 than for either the DPP8 or DPP9 enzymes (400- and 75- fold, respectively). The active metablite of saxagliptin is two-fold less potent than the parent. Both Saxagliptin and its metabolite are highly selective (>4000-fold) for the prevention of DPP4 compared with a range of other proteases (selectivity of sitagliptin and vildagliptin for DPP4 is >2600 and <250-fold, respectively, compared with DPP8 and DPP9). [2] Saxagliptin reduces the degradation of the incretin hormone glucagon-like peptide-1, thereby enhancing its actions, and is associated with improved β-cell function and suppression of glucagon secretion. [3]
Storage	Powder: -20°C for 3 years \| In solvent: -80°C for 1 year \| Shipping with blue ice.
Solubility Information	DMSO : 50 mg/mL (102.25 mM) Ethanol : 33 mg/mL (67.5 mM) H2O : < 1 mg/mL (insoluble or slightly soluble)
Keywords	lung \| Ki 16198 \| inhibit \| Inhibitor \| LPL Receptor \| BxPC-3 \| liver metastasis \| Ki-16198 \| Ki16198 \| Lysophospholipid Receptor
Inhibitors Related	Radioprotectin-1 \| Fingolimod hydrochloride \| SLP9101555 \| Tyloxapol \| ASP-4058 \| CYM50260 \| Tetradecyl Phosphonate \| Siponimod \| Fingolimod \| UCM-05194 \| S1PR1 modulator 1 \| Ozanimod
Related Compound Libraries	Anti-Pancreatic Cancer Compound Library \| Bioactive Compound Library \| Bioactive Compounds Library Max \| GPCR Compound Library

Company Profile Introduction

Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers. TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.